ArticleChemistry & biodiversity2026
Metabolomics and Mechanistic Approaches Reveal the Synergistic and Attenuating of Rubus chingii Hu on Tripterygium Glycoside Tablets in the Treatment of Rheumatoid Arthritis.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tripterygium Glycoside Tablets (TGTs) are primary drugs for rheumatoid arthritis (RA) but pose a risk of nephrotoxicity. Rubus chingii Hu (RCH) may enhance kidney function. This study explores a combined RA treatment by examining RCH's chemical components and using a collagen-induced arthritis (CIA) rat model to test TGTs with or without RCH. RCH boosted the therapeutic impact of TGTs in CIA rats, shown by decreased paw swelling, improved joint condition, and reduced serum TNF-α, IL-6, and IL-1β levels. The normalization of renal markers (BUN and Scr) and oxidative stress indicators (ROS, T-NOS, and T-SOD) may be associated with the Nrf2/NF-κB pathway. Metabolomics indicated that RCH may counteract nephrotoxicity by influencing the metabolism of glycine, serine, threonine, tryptophan, histidine, taurine, and sulfaurine. In summary, RCH synergizes with TGTs to treat RA by inhibiting inflammation, affecting metabolic pathways, reducing oxidative stress, and minimizing kidney toxicity, offering a new treatment strategy for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.